Details of the Drug Combination

General Information of Drug Combination (ID: DCPQB8U)

Drug Combination Name

Lomustine SCH-900776

Indication

Disease Entry	Status	REF
Malignant melanoma	Investigative	[1]

Component Drugs

Lomustine DMMWSUL

SCH-900776 DM67EMK

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: A375

Zero Interaction Potency (ZIP) Score: 7.5

Bliss Independence Score: 10.22

Loewe Additivity Score: 7.04

LHighest Single Agent (HSA) Score: 12.11

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Lomustine

Disease Entry	ICD 11	Status	REF
Brain cancer	2A00	Approved	[2]
Central nervous system neoplasm	N.A.	Approved	[3]
Primitive neuroectodermal tumor	N.A.	Approved	[3]
Classic Hodgkin lymphoma	N.A.	Investigative	[3]

Lomustine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Inhibitor	[5]
------------------------------------------------------------------------------------

Lomustine Interacts with 5 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[6]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Increases Expression	[7]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[8]
DNA polymerase eta (POLH)	OTN07WXU	POLH_HUMAN	Increases Expression	[9]
Methylated-DNA--protein-cysteine methyltransferase (MGMT)	OT40A9WH	MGMT_HUMAN	Decreases Response To Substance	[10]
------------------------------------------------------------------------------------

Indication(s) of SCH-900776

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]

SCH-900776 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Checkpoint kinase-1 (CHK1)	TTTU902	CHK1_HUMAN	Inhibitor	[11]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Breast and ovarian cancer syndrome	DC3YOTX	UWB1289+BRCA1	Investigative	[12]
Breast carcinoma	DCGKLP4	KPL1	Investigative	[12]
Breast carcinoma	DCK0390	OCUBM	Investigative	[12]
Colon carcinoma	DCMFRHQ	RKO	Investigative	[12]
Adenocarcinoma	DC3BV33	CAOV3	Investigative	[1]
Adenocarcinoma	DC2EPM7	A427	Investigative	[1]
Adenocarcinoma	DC1BEJC	NCIH1650	Investigative	[1]
Adenocarcinoma	DCN2YBN	NCIH2122	Investigative	[1]
Adenocarcinoma	DC45KXH	NCIH23	Investigative	[1]
Adenocarcinoma	DCX4JWN	COLO320DM	Investigative	[1]
Adenocarcinoma	DCEUH1X	HCT116	Investigative	[1]
Adenocarcinoma	DC64ASW	HT29	Investigative	[1]
Amelanotic melanoma	DCUFNLS	A2058	Investigative	[1]
Malignant melanoma	DCMPILU	RPMI7951	Investigative	[1]
Malignant melanoma	DCE774H	SKMEL30	Investigative	[1]
Mesothelioma	DCVOQCN	MSTO	Investigative	[1]
Non small cell carcinoma	DCYWW4F	SKMES1	Investigative	[1]
Ovarian endometrioid adenocarcinoma	DCX0734	A2780	Investigative	[1]
Ovarian serous cystadenocarcinoma	DC2VN67	SK-OV-3	Investigative	[1]
Prostate carcinoma	DCZGVUP	LNCAP	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 DrugCom(s)

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7214).
3	Lomustine FDA Label
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7943).
5	Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds. Acta Pol Pharm. 2007 Jan-Feb;64(1):27-33.
6	Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
7	High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2017 Mar;91(3):1367-1383. doi: 10.1007/s00204-016-1781-0. Epub 2016 Jun 29.
8	Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
9	Translesion polymerase is upregulated by cancer therapeutics and confers anticancer drug resistance. Cancer Res. 2014 Oct 1;74(19):5585-96. doi: 10.1158/0008-5472.CAN-14-0953. Epub 2014 Aug 14.
10	Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res. 2004;10(3):133-41. doi: 10.1007/BF03033741. Epub 2004 Sep 25.
11	Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
12	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165